Time filter

Source Type

Patent
Jiangsu Hengrui Medicine Co. and Shanghai Hengrui Pharmaceutical Co. | Date: 2016-11-01

Intermediate compounds used in the preparation of pyrrole six-membered heteroaryl ring derivatives are disclosed. In particular, compounds of formula (IB) are disclosed. The compounds of formula (IB) are used in the synthesis of Janus kinase (JAK) inhibitors. Substituents in formula (IB) have the same definitions as in the description.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2017-02-22

The present invention relates to amide derivatives and pharmaceutically acceptable salts thereof, preparation method therefor and medicinal application thereof. Specifically, the present invention relates to amide derivatives represented by general formula (I), preparation method therefor, pharmaceutical compositions containing the derivatives, and use thereof as therapeutic agent, especially as inhibitor for microsomal prostaglandin E synthase-1(mPGES-1), and use in preparation of medicines for treating and/or preventing diseases or illness such as inflammation and/or pain etc. The definition of each substituent group in general formula (I) is the same as the definition in the description.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-10-19

The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-12-07

The present invention relates to a ligand-cytotoxic drug conjugate, preparation method and pharmaceutical use thereof. More specifically, the present invention provides a ligand-cytotoxic drug conjugate of general formula Pc-(X-Y-D)_(n) , their preparation method and use of the ligand-cytotoxic drug conjugate and a pharmaceutical composition containing the same in the preparation of a medicament for the treatment of cancer via receptor modulation.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-03-23

The present invention relates to a cycloalkyl acid derivative, a preparation method thereof, and a pharmaceutical application thereof, and in particular, the present invention relates to a cycloalkyl acid derivative represented by general formula (I) and a medical salt thereof, a preparation method thereof, and an application of the cycloalkyl acid derivative and the medical salt thereof as URAT1 inhibitors, and particularly as therapeutic agents for diseases related to an abnormal uric acid level, wherein definitions of substituent groups in general formula (I) are the same as definitions in the specifications.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-08-31

The present invention relates to pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof. Specifically, the present invention relates to pyridic ketone derivatives represented by a general formula (I) and pharmaceutical salts thereof, method of preparing same, and use thereof as MEK inhibitors and especially as therapeutic agents for cancer, where the definitions of the substituents in the general formula (I) are the same as the definitions in the specification.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-09-28

Provided is an antibody capable of specially recognizing IL-17A and being combined with IL-17A. The antibody can be used for treating inflammations and autoimmune diseases caused by high expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, inflammatory arthritis.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-11-16

The present invention relates to an IL-15 heterodimeric protein and uses thereof and further relates to an IL-15/IL-15R heterodimeric protein. The IL-15 heterodimeric protein comprises protein (I) and protein (II), wherein said protein (I) is reassembled and formed by IL-15 or its variant with a first Fc variant; wherein said protein (II) is the second Fc variant, or reassembled and formed by IL-15R or its variant with a second Fc variant. The first Fc variant and the second Fc variant are linked via Knob-into-Hole mode. The IL-15 heterodimeric protein of the present invention has significant anti-tumor activity, better biological activity and prolonged in vivo half-life compared to IL-15 molecule alone.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-09-07

The present invention provides pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof. Specifically, the present invention provides pyrazolopyrimidone or pyrrolotriazone derivatives represented by a general formula (I) and pharmaceutical salts thereof, method of preparing same, and use thereof as a gonadotropin releasing hormone (GnRH) antagonist and especially as therapeutic agents for endometriosis, where the definitions of the substituents in the general formula (I) are the same as the definitions in the specification.


Patent
Shanghai Hengrui Pharmaceutical Co. and Jiangsu Hengrui Medicine Co. | Date: 2016-09-14

Disclosed are a human relaxin analogue, polynucleotide for encoding the human relaxin analogue, a pharmaceutical composition of the human relaxin analogue, and a pharmaceutical application of the human relaxin analogue. Further disclosed is a derivative of the human relaxin analogue.

Loading Shanghai Hengrui Pharmaceutical Co. collaborators
Loading Shanghai Hengrui Pharmaceutical Co. collaborators